Clinical Research Directory

* Inclusion Criteria: * Ability to provide written informed consent * Adult patients ≥18 years of age * First living-donor kidney transplant recipients * Estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m² at screening * Receiving standard immunosuppressive therapy (tacrolimus, mycophenolate mofetil, and prednisone) with induction therapy (thymoglobulin or basiliximab) * Exclusion Criteria: * Type 1 diabetes mellitus * Recipients of deceased donor kidney transplant * History of any other solid organ transplant * Second kidney transplant * Severe cardiovascular disease (congestive heart failure class IV, recent myocardial infarction, unstable angina, stroke, or transient ischemic attack within 8 weeks prior to enrollment) * HbA1c \>12% in patients with diabetes mellitus * Current use of SGLT2 inhibitors at enrollment * Known hypersensitivity or intolerance to SGLT2 inhibitors * Pregnant or breastfeeding women * Hepatic impairment (AST or ALT \>3 times the upper limit of normal, or total bilirubin \>2 times the upper limit of normal at enrollment) * Antibody-mediated rejection (AMR) or Banff grade ≥2A acute cellular rejection during the first week post-transplant * Use of anticoagulants, nonsteroidal anti-inflammatory drugs, pentoxifylline, or mineralocorticoid receptor antagonists (spironolactone, eplerenone, finerenone) * Highly sensitized recipients or presence of donor-specific antibodies prior to enrollment * Urological disorders (including recurrent urinary tract infections or urolithiasis within 12 months prior to enrollment) or severe genital infections * Presence of de novo or recurrent glomerulopathy or BK virus nephropathy during the first week post-transplant.